FAQs -HRSA-26-052.pdf
PDF 63 KB Posted
- Opportunity number
- HRSA-26-052
About this file
This is a Frequently Asked Questions (FAQs) document for HRSA 26-052, the Sickle Cell Disease Regional Care Excellence (SoRCE) Program funding opportunity.
The SoRCE Program has a four-year project period from September 1, 2026, through August 31, 2030. Each Regional Coordinating Hub (RCH) must contract with at least three Clinical-Community Spokes (CCSs), with each CCS comprising one clinical center partnered with at least one community-based organization (CBO). The CCS requirement must account for at least 40% of the total budget, after which remaining funds may support other clinical sites without CBO partnerships. Subawards and contracts do not need to be finalized before application submission; however, supporting documentation such as Letters of Support or Memoranda of Understanding must clearly describe roles, relationships, and deliverables. Within six months of award, the RCH must develop a regional action plan to support partnership, collaboration, and resource sharing across all CCSs. The SoRCE emerging issues supplement is available for up to $250,000 per year as a one-time, one-year award in any of the four project years, contingent on fund availability and appropriation. Supplement applications must be submitted with the initial base application and will be funded based on the applicant's objective review score ranking. The emerging issues supplement does not count toward the application page limit.
FAQs - SoRCE Questions_6.11.26.pdf
View the file
Other files
| File | Type | Posted |
|---|---|---|
| FAQs HRSA-26-052.pdf | ||
| HRSA-26-052 TA Call Presentation.pdf | ||
| FAQs - SoRCE Questions_6.11.26.pdf | ||
| HRSA-26-052 Final.pdf | ||
| HRSA-26-052 Final.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
FAQs – Sickle Cell Disease Regional Care Excellence Program (SoRCE)
HRSA 26-052
Q: What is the project period for HRSA 26-052, the Sickle Cell Disease Regional Care Excellence (SoRCE) Program funding opportunity?
A: The project period is four years, starting on 9/1/2026 and ending on 8/31/2030.
Q: Can one CBO partner with three other clinical sites to meet the Clinical Community Spoke (CCS) requirements for the region?
A: See page 5 of the NOFO (see Program Structure section): Each Regional Coordinating Hub (RCH) must contract with at least three Clinical-Community Spokes (CCSs) in their region. Each CCS includes one clinical center partnered with at least one community-based organization (CBO).
See page 39 of the NOFO: The panel reviewing NOFO applications will look to see how well applications describe plans to reach every person with Sickle Cell Disease (SCD) in the region through at least three CCSs.
Q: Do subawards have to be established before our application is submitted?
A: No. If you include documents that confirm actual or pending contracts or agreements (e.g., Letter of Support, Memorandum of Understanding, etc.), the documents should clearly describe the roles of subrecipients and contractors and any deliverables. It is not necessary to include the entire contents of lengthy agreements, so long as the portions you include describe the working relationship between you and the other (See pg. 34 of the NOFO under Attachment 5 for more information).
Please note that within six months, the RCH must develop a regional action plan to support partnership, collaboration, and resource sharing across all CCSs in the region. (See page 13 of the NOFO).
Q: Does the SoRCE emerging issues supplement count towards the page limit?
A: No. The SoRCE emerging issues supplement does not count towards the page limit.
Please see page 24 of the NOFO for the list of items that are included in the page limit.
Q: How is the supplement awarded?
A: Depending on the availability and appropriation of funds, supplemental funding may be awarded in any of the four project years. If applicants are interested in receiving supplemental funds, they must include their supplement application as part of their initial application. These are onetime, one-year supplements for up to $250,000 per year.
Supplements will be funded in the order of the objective review score earned by the applicant in the base competition. Please see page 34 of the NOFO for more information.
https://www.grants.gov/search-results-detail/360997 https://www.grants.gov/search-results-detail/360997 https://www.grants.gov/search-results-detail/360997
Q: After meeting the CCS requirement to contract with at least three Clinical- Community Spokes (CCSs) in the region, can we provide funds to clinical sites in our region that do not have a partnership with a CBO?
A: Yes. See page 5 of the NOFO (see Program Structure section): Each Regional Coordinating Hub (RCH) must contract with at least three Clinical-Community Spokes (CCSs) in their region. After meeting the requirement to have contracts with at least 3 CCCs in your region accounting for at least 40% of your budget, the remaining part of your budget can support other clinical sites in your region that do not have a partnership with a Community-Based Organization (CBO).
File details come from the government source that posted it. Updated .